Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial

Background and aimsAllergic asthma has a considerable burden on the quality of life. A significant portion of moderate-to-severe allergic asthma patients need omalizumab, an anti-immunoglobulin-E monoclonal antibody, as an add-on therapy. In this phase III clinical trial P043 (Zerafil®, CinnaGen, Ir...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Mostafa Ghanei, Babak Ghalebaghi, Ramin Sami, Mehdi Torabizadeh, Majid Mirsadraee, Babak Amra, Marzieh Tavakol, Hanieh Raji, Morteza Fallahpour, Arda Kiani, Atefeh Abedini, Farahzad Jabbari Azad, Seyed Alireza Mahdaviani, Davood Attaran, Mohammad Samet, Sasan Tavana, Maryam Haddadzadeh shoushtari, Javad Nazari, FatemehAlsadat AghaeiMeybodi, Mohammad Reza Fazlollahi, Ramin Ghasemi, Araz Sabzvari, Hamidreza Kafi, Esmaeil Idani
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	asthma omalizumab biosimilar IgE allergic
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1425906/full